Supraventricular tachycardia

Cardiovascular Centers of America Announces Cardiac Ablation Service Line at Advanced Heart and Vascular in Deltona, Florida

Retrieved on: 
Wednesday, April 17, 2024
Patient, Node, Education minister, Volusia County, Florida, Risk, Supraventricular tachycardia, ASC, AFIB, CCA, Obesity, SVT, Physician, Hypertension, Abdominal ultrasonography, Health, Atrioventricular node, Ageing, Atrial fibrillation, Prevalence, Pharmaceutical industry

DELTONA, Fla., April 17, 2024 /PRNewswire/ -- Cardiovascular Centers of America (CCA) proudly announces the launch of Florida's the first complete cardiac ablation service line in an Ambulatory Surgery Center (ASC) at Advanced Heart and Vascular Surgery Center (Advanced Cardiovascular).

Key Points: 
  • DELTONA, Fla., April 17, 2024 /PRNewswire/ -- Cardiovascular Centers of America (CCA) proudly announces the launch of Florida's the first complete cardiac ablation service line in an Ambulatory Surgery Center (ASC) at Advanced Heart and Vascular Surgery Center (Advanced Cardiovascular).
  • The team at Advanced Cardiovascular  successfully performed the inaugural AFIB ablation procedure within a Florida ASC setting in April 2024.
  • Cardiovascular Centers of America proudly announces the launch of Fla.'s first complete cardiac ablation service line.
  • In addition to the AFIB milestone, Advanced Cardiovascular is also one of the first ASCs in Florida to perform SVT and AV Node cardiac ablation procedures, providing another vital treatment option.

AOP Health Receives Market Authorization for Landiolol in Canada

Retrieved on: 
Wednesday, December 13, 2023
Biotechnology, Hospitals, Health, Pharmaceutical, Cardiology, Health Canada, AOP, Landiolol, Therapy, Patient, Multimedia, Atrial fibrillation, Atrial flutter, Supraventricular tachycardia, Hospital

At the end of November 2023, AOP Orphan Pharmaceuticals GmbH (AOP Health), an Austrian pharmaceutical company based in Vienna, received authorization from the Canadian Health Authority (Health Canada) for its ultra-short-acting, cardioselective β1-blocker Landiolol.

Key Points: 
  • At the end of November 2023, AOP Orphan Pharmaceuticals GmbH (AOP Health), an Austrian pharmaceutical company based in Vienna, received authorization from the Canadian Health Authority (Health Canada) for its ultra-short-acting, cardioselective β1-blocker Landiolol.
  • The authorization allows a certain group of intensive care patients access to an additional therapy option.
  • In addition, it opens the door to the North American market for AOP Health.
  • In Canada, Landiolol will only be available in hospitals.

Kestra Medical Technologies Offers Electrophysiology and Cardiology Clinicians Opportunity to Wear ASSURE WCD System at #HRX2023 Conference

Retrieved on: 
Friday, September 22, 2023
Biotechnology, Medical Devices, Health, Health Technology, Cardiology, SVT, Arrest, Health technology, Multimedia, Heart Rhythm Society, Photograph, WCD, Patient, Electrophysiology, Risk, ACE, Conference, Arrhythmia, Female, Supraventricular tachycardia, Medical device

Clinicians that participate will be measured, fit, and trained in the use of a demonstration ASSURE WCD System and experience everyday usage of the ASSURE system while participating in conference activities.

Key Points: 
  • Clinicians that participate will be measured, fit, and trained in the use of a demonstration ASSURE WCD System and experience everyday usage of the ASSURE system while participating in conference activities.
  • View the full release here: https://www.businesswire.com/news/home/20230922082496/en/
    Kestra Medical Technologies launched the ASSURE Clinician Experience (ACE) at The Heart Rhythm Society #HRX2023 Conference in Seattle.
  • The program lets electrophysiology and cardiology clinicians wear and simulate use of the ASSURE WCD System to experience how the system was designed for comfort and to promote patient confidence and usage compliance.
  • (Photo credit: Kestra Medical Technologies, Inc.)
    “Wearable defibrillators (WCDs) work when patients wear them,” said Laura Gustavson, Vice President of Clinical Marketing.

Viz.ai Signs License Agreement with UCSF to Commercialize Three Cardiac Artificial Intelligence Algorithms

Retrieved on: 
Friday, August 25, 2023
Software, Apps, Applications, Technology, Medical Devices, Hospitals, University, Artificial Intelligence, Health Technology, Education, Surgery, Cardiology, Nursing, Health, Heart, Cardiovascular disease, Cardiac amyloidosis, ECG, University of California, Technology management, UCSF, Algorithm, Knowledge, AI, Pulmonary hypertension, Automated ECG interpretation, Death, Supraventricular tachycardia, Disease, Medical device

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced that it has signed an exclusive agreement with University of California, San Francisco (UCSF) to commercialize three AI algorithms for the automated detection of cardiovascular diseases.

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced that it has signed an exclusive agreement with University of California, San Francisco (UCSF) to commercialize three AI algorithms for the automated detection of cardiovascular diseases.
  • Developed at UCSF by leading researchers, these AI algorithms to detect cardiac amyloidosis, pulmonary hypertension, and supraventricular tachycardia are based on analysis of electrocardiograms (ECGs), the most widely used diagnostic test for characterization of cardiac structure and electrical activity of the heart.
  • “Collectively, cardiac amyloidosis, pulmonary hypertension, and supraventricular tachycardia affect up to 75 million people worldwide and are extremely difficult to detect or can take years to diagnose.
  • “We are proud to work with UCSF to develop more AI-powered tools that can advance cardiac care.”

Milestone Pharmaceuticals Announces Presentation of Data from Analysis of Etripamil Nasal Spray in Patients Experiencing Atrial Fibrillation with Rapid Ventricular Rate

Retrieved on: 
Monday, May 22, 2023
KOL, University, FHRS, HRS, Atrial fibrillation, Anxiety, Aes, ECG, Milestone, History, VR, MHS, Cardiac electrophysiology, MSC, University of Toronto, Patient, Population health, Annual general meeting, St. Michael's Hospital, Paroxysmal supraventricular tachycardia, Hospital, Heart rate, Safety, News, Supraventricular tachycardia, Pharmaceutical industry, Ventricular fibrillation, PSVT, MD, Pharmacology, Medicine

MONTREAL and CHARLOTTE, N.C., May 22, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced promising data from an ad hoc analysis of a subset of patients experiencing atrial fibrillation with rapid ventricular rate (AFib-RVR) in the NODE-303 study, which evaluated etripamil, the Company's investigational calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT). The data were featured during an oral session at the Heart Rhythm 2023 Annual Meeting.

Key Points: 
  • "Data from this unplanned analysis represent the first direct clinical evidence of the impact of etripamil on heart rate in patients experiencing an event of AFib-RVR," said Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals.
  • We are firmly committed to our mission of unlocking the full potential of etripamil to serve as a self-administered, on-demand treatment for patients facing episodic cardiovascular conditions associated with rapid heart rate."
  • Enrollment continues in ReVeRA, Milestone's Phase 2 double-blind, placebo-controlled, proof-of-concept trial of etripamil nasal spray in emergency-department patients experiencing AFib-RVR.
  • To access the live call by phone, dial (877) 870-4263 (domestic) or (412) 317-0790 (international) and ask to be connected to the Milestone Pharmaceuticals call.

Global Electrophysiology Market Report 2022: Sector to Reach $12.27 Billion by 2028 at a 9% CAGR - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 3, 2023
Health, Cardiology, Heart, SVT, ASCS, Obesity, Prevalence, Diabetes, Marketing, Atrial fibrillation, DSM-IV codes, Ortho Clinical Diagnostics, MEA, USD, Incidence, Hospital, Ventricular tachycardia, Developed country, Patient, Application, Electrophysiology, Plant growth analysis, VPS, Primary, Growth, Arrhythmia, End Use Energy Demand Centres, Supraventricular tachycardia, Medical device

Global Electrophysiology Market size was valued at USD 6.65 billion in 2021, and it is expected to reach a value of USD 12.27 billion by 2028, at a CAGR of more than 9.14% over the forecast period (2022- 2028).

Key Points: 
  • Global Electrophysiology Market size was valued at USD 6.65 billion in 2021, and it is expected to reach a value of USD 12.27 billion by 2028, at a CAGR of more than 9.14% over the forecast period (2022- 2028).
  • A variety of goods, including electrophysiology catheters, electrophysiology laboratory equipment, electrophysiology recording systems, and electrophysiology ablation catheters, are available on the electrophysiology market.
  • Top-down and bottom-up approaches were used to estimate and validate the size of the Global Electrophysiology Market and to estimate the size of various other dependent submarkets.
  • Another trend in the electrophysiology market is the adoption of robotic-assisted procedures, which offer greater precision and accuracy in performing electrophysiology procedures.

End Drug Shortages Alliance Releases Report for Drugs Impacted by Pharmaceutical Plant Closure

Retrieved on: 
Wednesday, March 15, 2023
Other Manufacturing, Medical Supplies, Hospitals, Transport, Manufacturing, Practice Management, General Health, Pharmaceutical, Health, Logistics, Supply Chain Management, Oklahoma Hospital Association, Risk, Dimercaprol, Hyperparathyroidism, Supraventricular tachycardia, ASHP, Patient, EDSA, Calcitriol, Organic acid, Knowledge, Akorn, Physostigmine, East End Drugs, Bankruptcy, Adenosine, CHA, Anticholinergic, Mayo Clinic, Kidney, Pharmaceutical industry, Risk management, Medical device, Nursing, Vizient, Inc.

The End Drug Shortages Alliance (EDSA) today released a report assessing the impact to the U.S. market caused by the recent closure of a drug manufacturer.

Key Points: 
  • The End Drug Shortages Alliance (EDSA) today released a report assessing the impact to the U.S. market caused by the recent closure of a drug manufacturer.
  • “Transparency regarding drug shortages is important to ensure patient care remains uninterrupted,” said Mittal Sutaria, senior vice president, Vizient pharmacy contract and program services and EDSA board member.
  • Clinicians and providers, to exercise a stewardship mindset and review purchasing and formulary status to determine conservation and mitigation strategies.
  • “Advance knowledge of supply disruptions is part of the transparency that the End Drug Shortages Alliance has advocated for since forming.

Mark Y. Lee, M.D., Named Medical Director of Electrophysiology at MemorialCare Heart & Vascular Institute at Long Beach Medical Center

Retrieved on: 
Thursday, January 19, 2023
Long Beach Medical Center, University, Cardiac electrophysiology, Education, FACC, Dartmouth–Hitchcock Medical Center, Cardiovascular disease, Internal medicine, Dysrhythmia, Ventricular tachycardia, Supraventricular tachycardia, Atrial fibrillation, Flecainide, Patient, Clinical trial, EP, Electrophysiology, Research, Hospital, Medical device

LONG BEACH, Calif., Jan. 19, 2023 /PRNewswire/ -- Mark Y. Lee, M.D ., FACC, has been named medical director of electrophysiology at MemorialCare Heart & Vascular Institute at Long Beach Medical Center .

Key Points: 
  • LONG BEACH, Calif., Jan. 19, 2023 /PRNewswire/ -- Mark Y. Lee, M.D ., FACC, has been named medical director of electrophysiology at MemorialCare Heart & Vascular Institute at Long Beach Medical Center .
  • As the new medical director of electrophysiology, Dr. Lee will work to further Long Beach Medical Center's efforts for electrophysiology clinical research and education.
  • "Dr. Lee has done amazing work to date at MemorialCare Heart & Vascular Institute at Long Beach Medical Center, and we are excited to have him take on this new role as medical director of electrophysiology," says Joe Kim, M.D., chief medical officer, MemorialCare Long Beach Medical Center.
  • "I was born at Long Beach Medical Center, so serving my local community these past seven years as an electrophysiologist has been a blessing," says Dr. Lee.

Weill Cornell Medicine partners with Poland-based company Cardiomatics to investigate the relationship between HIV and heart rhythm disorders

Retrieved on: 
Monday, December 12, 2022
Biozentrum University of Basel, Degenerative disease, Arrhythmia, Physician, Smartphone, United Kingdom, HIV, MD, HRV, Public health, Patient, Software as a service, Practitioner, Research, Cardiovascular disease, Supraventricular tachycardia, Intelligence, Medical school, FDA, Workload, Sleep, AI, Weill Cornell Medicine, ECG, Data analysis, Medical University of Warsaw, Artificial intelligence, Cardiology, Clinical trial, University, IT University of Copenhagen, Machine learning, Nursing, Algorithm, Risk, Medical device, Medical imaging, Pharmaceutical industry

Cardiomatics is a certified online SaaS platform, created by experts with experience in developing artificial intelligence and machine learning.

Key Points: 
  • Cardiomatics is a certified online SaaS platform, created by experts with experience in developing artificial intelligence and machine learning.
  • Recently, Cardiomatics advanced algorithms have also facilitated the work of scientists from Weill Cornell Medicine in New York.
  • Cardiomatics offered us timely information and customer service, and the opportunity to generate customizable reports from the data that we are collecting.
  • This helps us respond to individual patients' conditions but also rapidly advance our research aims.- emphasized Cody Cichowitz, MD from Weill Cornell Medicine.

Weill Cornell Medicine partners with Poland-based company Cardiomatics to investigate the relationship between HIV and heart rhythm disorders

Retrieved on: 
Monday, December 12, 2022
Biozentrum University of Basel, Degenerative disease, Arrhythmia, Physician, Smartphone, United Kingdom, HIV, MD, HRV, Public health, Patient, Software as a service, Practitioner, Research, Cardiovascular disease, Supraventricular tachycardia, Intelligence, Medical school, FDA, Workload, Sleep, AI, Weill Cornell Medicine, ECG, Data analysis, Medical University of Warsaw, Artificial intelligence, Cardiology, Clinical trial, University, IT University of Copenhagen, Machine learning, Nursing, Algorithm, Risk, Medical device, Medical imaging, Pharmaceutical industry

Cardiomatics is a certified online SaaS platform, created by experts with experience in developing artificial intelligence and machine learning.

Key Points: 
  • Cardiomatics is a certified online SaaS platform, created by experts with experience in developing artificial intelligence and machine learning.
  • Recently, Cardiomatics advanced algorithms have also facilitated the work of scientists from Weill Cornell Medicine in New York.
  • Cardiomatics offered us timely information and customer service, and the opportunity to generate customizable reports from the data that we are collecting.
  • This helps us respond to individual patients' conditions but also rapidly advance our research aims.- emphasized Cody Cichowitz, MD from Weill Cornell Medicine.